Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010
Lauri E. Markowitz,Susan Hariri,Carol Y. Lin,Eileen F. Dunne,Martin Steinau,Geraldine M. McQuillan,Elizabeth R. Unger +6 more
Reads0
Chats0
TLDR
Within 4 years of vaccine introduction, the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake, and the estimated vaccine effectiveness was high.Abstract:
Background. Human papillomavirus (HPV) vaccination was introduced into the routine immunization schedule in the United States in late 2006 for females aged 11 or 12 years with catch-up vaccination recommended for those aged 13-26 years. In 2010 3-dose vaccine coverage was only 32% among 13-17 year-olds. Reduction in the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6 -11 -16 and -18) will be one of the first measures of vaccine impact. Methods. We analyzed HPV prevalence data from the vaccine era (2007-2010) and the prevaccine era (2003-2006) that were collected during National Health and Nutrition Examination Surveys. HPV prevalence was determined by the Linear Array HPV Assay in cervicovaginal swab samples from females aged 14-59 years; 4150 provided samples in 2003-2006 and 4253 provided samples in 2007-2010. Results. Among females aged 14-19 years the vaccine-type HPV prevalence (HPV-6 -11 -16 or -18) decreased from 11.5% (95% confidence interval [CI] 9.2-14.4) in 2003-2006 to 5.1% (95% CI 3.8-6.6) in 2007-2010 a decline of 56% (95% CI 38-69). Among other age groups the prevalence did not differ significantly between the 2 time periods (P > .05). The vaccine effectiveness of at least 1 dose was 82% (95% CI 53-93). Conclusions. Within 4 years of vaccine introduction the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake. The estimated vaccine effectiveness was high.read more
Citations
More filters
Journal ArticleDOI
Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016).
Carrie R. H. Innes,Peter Sykes,Dianne Harker,Jonathan Williman,Rachael van der Griend,Martin Whitehead,Merilyn Hibma,Beverley Lawton,Peter C. FitzGerald,Narena M. Dudley,Simone Petrich,Jim Faherty,Cecile Bergzoll,Lois Eva,Lynn Sadler,Bryony Simcock +15 more
TL;DR: The reducing proportion of cervical intraepithelial neoplasia grade 2 (CIN2) lesions associated with HPV genotypes 16 and 18 changed over time in young women recruited to a prospective CIN2 observational management trial between 2013 and 2016.
Journal ArticleDOI
Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.
TL;DR: Prospective effectiveness studies of recommended 2-dose schedules against clinical endpoints including persistent infection, genital warts, and cervical dysplasia are necessary to ensure long-term protection of vaccinated cohorts.
Journal ArticleDOI
HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial
Thomas C. Wright,Valentin Parvu,Mark H. Stoler,Salma Kodsi,Karen Eckert,Karen Yanson,Charles K. Cooper +6 more
TL;DR: A lower HPV prevalence in older, vaccinated women suggests that "catch-up" vaccination provides benefit, and women with a prior history of HPV vaccination have a lower prevalence of any high-risk HPV, HPV 16, 18, 31, and 33/58.
Journal ArticleDOI
Timing Is Everything: Exploring Parental Decisions to Delay HPV Vaccination.
TL;DR: The results suggest that vaccination delays are not merely a matter of scientific doubt but also based on parents’ perceptions of their child’s sexual readiness, and thus potentially more difficult to overcome.
Journal ArticleDOI
NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy.
TL;DR: In this article, the authors focused on recent discoveries about using NK cells to prevent and treat cervical cancer and the possibility of cellular immunotherapy becoming one of the best strategies to exploit the immune system to fight tumours.
References
More filters
Journal ArticleDOI
A review of human carcinogens--Part B: biological agents
Véronique Bouvard,Robert Baan,Kurt Straif,Yann Grosse,Béatrice Secretan,Fatiha El Ghissassi,Lamia Benbrahim-Tallaa,Neela Guha,Crystal Freeman,Laurent Galichet,Vincent Cogliano +10 more
TL;DR: In this paper, the carcinogenicity of the biological agents classifi ed as "carcinogenic to humans" (Group 1) and to identify additional tumour sites and mechanisms of carcinogenesis (tables 1 and 2).
Journal ArticleDOI
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjosé,Wim Quint,Laia Alemany,D.T. Geraets,Jo Ellen Klaustermeier,Belen Lloveras,Sara Tous,Ana Félix,Luis Eduardo Bravo,Hai Rim Shin,Carlos S. Vallejos,Patricia Alonso de Ruiz,Marcus Aurelho Lima,Núria Guimerà,Omar Clavero,Maria Alejo,Antonio Llombart-Bosch,Chou Cheng-Yang,Silvio Tatti,Elena Kasamatsu,Ermina Iljazovic,Michael Odida,Rodrigo Prado,Muhieddine Seoud,Magdalena Grce,Alp Usubutun,Asha Jain,Gustavo Adolfo Hernandez Suarez,Luis Estuardo Lombardi,Aekunbiola Banjo,Clara Menendez,Efren J. Domingo,Julio Velasco,Ashrafun Nessa,Saibua Chichareon,You-Lin Qiao,Enrique Lerma,Suzanne M. Garland,Toshiyuki Sasagawa,Annabelle Ferrera,Doudja Hammouda,Luciano Mariani,Adela Pelayo,Ivo Šteiner,Esther Oliva,Chris J. L. M. Meijer,Waleed Al-Jassar,Eugenia Cruz,Thomas C. Wright,Ana Puras,Cecilia L. Llave,Maria Tzardi,Theodoros Agorastos,Victoria Garcia-Barriola,Christine Clavel,Jaume Ordi,Miguel Andújar,Xavier Castellsagué,Gloria I. Sanchez,Andrzej Nowakowski,Jacob Bornstein,Nubia Muñoz,F. Xavier Bosch +62 more
TL;DR: HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines, according to this largest assessment of HPV genotypes to date.
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal ArticleDOI
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Jorma Paavonen,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song-Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Julio Cesar Teixeira,S R Skinner,James Hedrick,Unnop Jaisamrarn,Genara Limson,Suzanne M. Garland,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Franz X. Bosch,David Jenkins,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Matti Lehtinen,Gary Dubin +26 more
TL;DR: The HPV- 16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.
Related Papers (5)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura,Anna R. Giuliano,Ole Erik Iversen,Céline Bouchard,Constance Mao,Jesper Mehlsen,Edson D. Moreira,Yuen Ngan,Lone Kjeld Petersen,Eduardo Lazcano-Ponce,Punnee Pitisuttithum,Jaime Alberto Restrepo,Gavin Stuart,Linn Woelber,Yuh Cheng Yang,Jack Cuzick,Suzanne M. Garland,Warner K. Huh,Susanne K. Kjaer,Oliver Bautista,Ivan S. F. Chan,Joshua Chen,Richard Gesser,Erin Moeller,Michael Ritter,Scott Vuocolo,Alain Luxembourg +26 more
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Suzanne M. Garland,Suzanne M. Garland,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Janine T. Bryan,Frank J. Taddeo,Radha Railkar,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Laura A. Koutsky +19 more
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano,Joel M. Palefsky,Stephen E. Goldstone,Edson D. Moreira,Mary E. Penny,Carlos Aranda,Eftyhia Vardas,Harald Moi,Heiko Jessen,Richard J. Hillman,Yen Hwa Chang,Daron G. Ferris,Danielle Rouleau,Janine T. Bryan,J. Brooke Marshall,Scott Vuocolo,Eliav Barr,David Radley,Richard M. Haupt,Dalya Guris +19 more